Dendritic cells (DCs) can initiate and direct adaptive immune responses. This ability is
exploitable in DC vaccination strategies, in which DCs are educated ex vivo to present tumor …

Dendritic cells (DC) are recognized as the most potent antigen-presenting cells with the
ability to stimulate naive resting T cells and to initiate primary immune responses …

Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective
antitumor immune response against tumor antigens and was first explored in a clinical trial …

Dendritic cells (DCs) are specialized immunostimulatory cells involved in the induction and
regulation of immune responses. The feasibility of large-scale ex vivo generation of DCs …

Early clinical trials, in which over 1000 cancer patients received dendritic cell (DC) vaccines,
tested different vaccine preparations, but they did not always induce sufficient acquired …

Dendritic cells (DCs) have shown great potential as a component or target in the landscape
of cancer immunotherapy. Different in vivo and ex vivo strategies of DC vaccine generation …

Cancer immunotherapy seeks to mobilize a patient's immune system for therapeutic benefit.
It can be passive, that is, transfer of immune effector cells (T cells) or proteins (antibodies), or …

Dendritic cells (DCs) are considered as professional antigen presenting cells (APCs),
containing a variety of subsets, that can be resident in organs or migrating among the …

Dendritic cell (DC)-based immunotherapy employs the patients' immune system to fight
neoplastic lesions spread over the entire body. This makes it an important therapy option for …

Cancer immunotherapy aims at eliciting an immune response directed against tumor
antigens to help fight off residual tumor cells and thereby improve survival and quality of life …